Daily Brief China: Transwarp Technology, Robotechnik Intelligent Te-A, Z.AI, Henderson Land Development, Contemporary Amperex Technology, Zhejiang Jingxin Pharmaceutical, Junshi Biosciences, Moonshot AI, Hunan Junxin Environmental Protection and more

• Transwarp Technology (688031 CH) , an AI infrastructure software provider, raised US$88m in its H-share listing.
• Transwarp Technology (Shanghai) Co (TTC) is an AI infrastructure software provider in China. TTC enables enterprises to build AI infrastructure software that drives intelligent transformation and business model innovation.
• We have looked at the past performance and likely A/H premium in our previous note. In this note, we talk about the trading dynamics.

• 2026 A+H IPOs have punished day-one buyers: Luxshare, Innolight and Longsys all closed below issue despite discounts of 13–44%.
• RoboTechnik’s photonics inflection is real, but FY27E at 372x EPS leaves almost no fundamental valuation support.
• Investment positioning: bid only at ≥30% discount, size for a weak open, stop at CNY545 and exit around Southbound eligibility.

• Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
• On the IPO front, National Stock Exchange (NSEIN IN) managed to garner interst from a long list of anchor investors, while GCash (Mynt) is said to be planning to launch.
• On the placement front, Tencent (700 HK) continues to trim its investment portfolio.

• Policy Pivot: The 2026 Policy Address prioritizes long-term supply and public housing, heavily favouring Northern Metropolis infrastructure over short-term mass-market property stimulus.
• Sector Impact: Mass-market buyers struggle under 50% DSR caps, while luxury inventory and commercial landlords benefit from targeted capital migration and stable yields.
• Actionable Trade: Buy Henderson Land (0012.HK). Its 45m sq ft agricultural land bank captures massive Northern Metropolis monetization, unlocking deep Sum-of-the-Parts value.

• WEEKLY tactical global macro recap/analysis for several markets and stocks we track, grouped by sector.
• We apply our quantitative models to each instrument’s trend, to determine which stocks/markets are just starting a trend, are in the middle of it, or are about to end it.
• Most overbought: Meta, Hitachi Ltd, SK Hynix  Most oversold: Meituan, ICICI Bank, HKEX and Clearing, Ping An Insurance, Contemporary Amperex Technology (CATL), Komatsu, Hanwha Solutions, Zijin Mining, Shin Etsu Chemical

• Zhejiang Jingxin Pharmaceutical is a group focused on CNS, cardiovascular, and cerebrovascular diseases, generating revenue from drugs, APIs, medical equipment, seeking a primary HKEX listing.
• Sole approved innovative drug, Dimdazenil, launched in 2024 for insomnia. Operates eleven manufacturing facilities, with largest customer accounting for 17.2% of revenue.
• Revenue was RMB4,069,361 and profit RMB771,731 in 2025. Profit for the period decreased by 10.0% to RMB358.0 million (six months ended June 30, 2026).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Junshi Biosciences (1877 HK) reported stellar performance for 1H26, with the company reporting its maiden net profit. Steady revenue growth of toripalimab led to breakthroughs in revenue and profit.
• Tuoyi is reporting increasing revenue in China, driven by continued expansion of indications and NRDL coverage. 2Q26 represents 11th consecutive quarter of sequential revenue increase for Tuoyi.
• Continued clinical advancement of core pipelines, including bispecific antibody candidate, JS207 and ADC candidate, JS212 with strong clinical trial data for various types of solid tumors enhance visibility beyond toripalimab.  

• Engineered Unit Economics: Moonshot AI’s widely publicized $1 billion ARR in August 2026 is highly synthetic, heavily reliant on “barter ARR” and non-cash cloud credit offsets from strategic investors like Alibaba and Tencent. Strip out these subsidized credits, and the true cash-generative ARR is estimated to be closer to $250 million to $300 million.
• Unviable Cost-to-Serve: The launch of the massive 2.8-trillion-parameter Kimi K3 in July 2026 has pushed Moonshot’s monthly cash burn to an unsustainable $120 million to $150 million. Gross margins are heavily depressed in the mid-30% range due to reliance on domestic hyperscaler clouds for compute.
• The Blacklist Race: The confidential Hong Kong IPO filing on September 2, 2026, represents an existential race against time. Moonshot is rushing to secure its $3 billion raise before impending US Treasury sanctions—sparked by proven, systematic model distillation campaigns against Anthropic’s Claude—force global institutional investors to divest.

• The space for new franchise projects in regional markets is becoming saturated. Junxin has almost achieved full coverage in Hunan, and the growth space of domestic stock market is limited.
• Ahead of Junxin’s development path lies both vast market space and unknown obstacles. 2026 will be a crucial year for testing Junxin’s strategic choice. High dividend is attractive to investors.
• Junxin’s overseas projects are still in the development stage and it will be difficult to generate substantial profits in short term. Valuation support mainly relies on the domestic core business.